Grufity logoGrufity logo

Jazz Pharmaceuticals PLC Stock Research

JAZZ

137.22USD+2.33(+1.73%)Delayed

Market Summary

USD137.22+2.33
Delayed
1.73%

JAZZ Alerts

JAZZ Stock Price

JAZZ RSI Chart

JAZZ Valuation

Market Cap

8.6B

Price/Earnings (Trailing)

-38.45

Price/Sales (Trailing)

2.35

EV/EBITDA

-39.3

Price/Free Cashflow

6.93

JAZZ Price/Sales (Trailing)

JAZZ Profitability

EBT Margin

-10.19%

Return on Equity

-7.26%

Return on Assets

-2.07%

Free Cashflow Yield

14.43%

JAZZ Fundamentals

JAZZ Revenue

Revenue (TTM)

3.7B

Revenue Y/Y

8.41%

Revenue Q/Q

3.35%

JAZZ Earnings

Earnings (TTM)

-224.1M

Earnings Y/Y

-580.95%

Earnings Q/Q

-1.1K%

Price Action

52 Week Range

125.36169.98
(Low)(High)

Last 7 days

-3.5%

Last 30 days

-10.9%

Last 90 days

-11.8%

Trailing 12 Months

-12.8%

JAZZ Financial Health

Current Ratio

2.79

Debt/Equity

1.86

Debt/Cashflow

0.22

JAZZ Investor Care

Shares Dilution (1Y)

2.45%

Diluted EPS (TTM)

-3.58

Peers (Alternatives to Jazz Pharmaceuticals)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
404.8B
94.9B
-5.16% -10.64%
22.56
4.26
1.25% -14.07%
296.8B
28.5B
-5.67% 20.74%
47.53
10.4
0.79% 11.88%
272.8B
59.3B
-1.75% 40.02%
17.88
4.63
21.72% 11.27%
226.4B
100.3B
-8.43% -20.95%
7.22
2.26
23.43% 42.74%
142.7B
46.2B
-7.78% -1.12%
22.55
3.09
-0.49% -9.54%
MID-CAP
4.8B
4.5B
-0.20% -5.41%
-34.17
1.08
7.56% -104.06%
3.3B
2.2M
105.10% 171.03%
-10.52
1.5K
-80.71% -4.88%
SMALL-CAP
1.9B
667.2M
-9.96% 17.66%
31.57
2.87
15.09% 13.64%
1.6B
602.5M
-17.77% -52.80%
-2.74
2.63
18.18% -18.59%
991.7M
478.9M
-11.35% -65.42%
-0.32
2.07
-31.50% -634.70%
792.9M
285.2M
-7.22% -37.95%
3.6
2.78
-27.21% -40.28%
768.8M
114.5M
-15.28% -37.42%
-4.56
6.72
27.90% 57.40%
541.5M
29.8M
-40.95% -47.43%
-6.23
18.2
340.05% 4.35%
400.7M
51.5M
-2.49% -0.39%
-5.64
7.78
18.32% -984.05%
94.1M
2.3B
-43.99% -88.43%
-0.03
0.04
-22.53% -376.66%

Financials for Jazz Pharmaceuticals

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue2.1%3,6593,5843,4813,3003,094
  S&GA Expenses-1.1%1,4171,4321,4371,5001,452
EBITDA-623.5%-342-47.34-54.66-122-
EBITDA Margin-608.6%-0.09*-0.01*-0.02*-0.04*-
Earnings Before Taxes-380.3%-372-77.62-85.12-242-112
EBT Margin-370.4%-0.10*-0.02*-0.02*-0.07*-
Interest Expenses-138----
Net Income-1099.0%-224-18.69-51.87-449-329
Net Income Margin-1074.3%-0.06*-0.01*-0.01*-0.14*-
Free Cahsflow15.3%1,2431,078921665-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets4.3%10,83510,38511,20011,76912,299
  Current Assets1.3%2,6062,5722,5912,5012,611
    Cash Equivalents5.0%881839711491591
  Inventory-1.9%7147288629851,073
  Goodwill6.3%1,6931,5931,6881,7821,828
  Current Liabilities14.8%933813705737809
  Long Term Debt-4.9%5,7276,0216,0246,050-
    LT Debt, Current0%31.0031.0031.0031.0031.00
    LT Debt, Non Current0.0%5,6935,6965,9905,9936,019
Shareholder's Equity12.4%3,0862,7453,2013,6083,965
  Retained Earnings-24.7%734974994959830
  Additional Paid-In Capital2.6%3,4773,3883,3123,2393,535
Shares Outstanding0.6%63.0062.0062.0062.00-
Cashflow (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations14.8%1,2721,108964702779
  Share Based Compensation4.0%222214210205189
Cashflow From Investing-238.2%-446-131-163-5,986-5,212
Cashflow From Financing33.5%-529-795-9713,6813,971
  Buy Backs-25.0%0.000.000.000.00-

Risks for JAZZ

What is the probability of a big loss on JAZZ?

69.6%


Probability that Jazz Pharmaceuticals stock will be more than 20% underwater in next one year

49.6%


Probability that Jazz Pharmaceuticals stock will be more than 30% underwater in next one year.

0%


Probability that Jazz Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does JAZZ drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Jazz Pharmaceuticals was unfortunately bought at previous high price.

Drawdowns

Returns for JAZZ

Cumulative Returns on JAZZ

8.6%


10-Year Cumulative Returns

1.6%


7-Year Cumulative Returns

-2.6%


5-Year Cumulative Returns

6.6%


3-Year Cumulative Returns

What are the long-term rolling returns for JAZZ?

FIve years rolling returns for Jazz Pharmaceuticals.

Annualized Returns

Which funds bought or sold JAZZ recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-32.2
-20,389,000
87,136,000
0.10%
2023-03-10
BAILLIE GIFFORD & CO
unchanged
-
4,764
26,764
-%
2023-03-06
Rockefeller Capital Management L.P.
added
4.74
1,244,000
6,182,000
0.03%
2023-03-02
OLIVER LAGORE VANVALIN INVESTMENT GROUP
reduced
-7.69
-88.00
1,912
-%
2023-02-28
Voya Investment Management LLC
reduced
-25.54
-973,130
7,870,870
0.01%
2023-02-24
SRS Capital Advisors, Inc.
unchanged
-
2,152
11,152
-%
2023-02-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
added
0.51
4,173,000
24,896,000
0.26%
2023-02-21
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
reduced
-3.24
52,530
385,530
-%
2023-02-21
MACQUARIE GROUP LTD
added
11.01
1,191,840
4,839,840
0.01%
2023-02-17
TRUIST FINANCIAL CORP
added
6.62
1,244,580
5,776,580
0.01%

1–10 of 45

Latest Funds Activity

Are funds buying JAZZ calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own JAZZ
No. of Funds

Jazz Pharmaceuticals News

MarketBeat

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CAO Sells $136284.06 ....

MarketBeat,
40 hours ago

GuruFocus.com

5 Stocks Gurus Are Trying Thei.

GuruFocus.com,
3 days ago

InvestorsObserver

Nasdaq

Yahoo Eurosport UK

Schedule 13G FIlings of Jazz Pharmaceuticals

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
9.61%
6,050,625
SC 13G/A
Jan 26, 2023
blackrock inc.
10.6%
6,652,382
SC 13G/A
Jan 20, 2023
blackrock inc.
10.6%
6,652,382
SC 13G
Jan 05, 2023
jpmorgan chase & co
4.6%
2,924,604
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Jan 28, 2022
blackrock inc.
10.5%
6,450,368
SC 13G/A
Jan 24, 2022
jpmorgan chase & co
5.2%
3,248,156
SC 13G
Feb 11, 2021
renaissance technologies llc
5.56%
3,099,050
SC 13G/A
Feb 10, 2021
vanguard group inc
8.76%
4,877,893
SC 13G/A
Feb 08, 2021
fmr llc
-
0
SC 13G

JAZZ Fair Value

Jazz Pharmaceuticals fair value in different scenarios

The table shows the Fair Value estimates for Jazz Pharmaceuticals for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

-

-

-

-

-

-

-

-

-

-
Current Inflation

89.88

-34.50%

110.26

-19.65%

153.07

11.55%

198.25

44.48%

231.66

68.82%
Very High Inflation

-

-

-

-

-

-

-

-

-

-

Historical Jazz Pharmaceuticals Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Jazz Pharmaceuticals

View All Filings
Date Filed Form Type Document
Mar 10, 2023
4
Insider Trading
Mar 09, 2023
4
Insider Trading
Mar 07, 2023
4
Insider Trading
Mar 07, 2023
4
Insider Trading
Mar 07, 2023
4
Insider Trading
Mar 07, 2023
4
Insider Trading
Mar 07, 2023
4
Insider Trading
Mar 07, 2023
4
Insider Trading
Mar 07, 2023
4
Insider Trading
Mar 07, 2023
4
Insider Trading

Latest Insider Trading transactions for JAZZ

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-08
Sablich Kim
sold
-421,043
139
-3,013
evp, gm of u.s., commercial ma
2023-03-07
O'Keefe Kenneth W
acquired
367,920
81.76
4,500
-
2023-03-07
Larkin Finbar
sold
-292,081
140
-2,075
svp, technical operations
2023-03-07
O'Keefe Kenneth W
sold
-372,268
138
-2,690
-
2023-03-06
Larkin Finbar
acquired
100,176
58.72
1,706
svp, technical operations
2023-03-06
Larkin Finbar
sold
-245,526
143
-1,706
svp, technical operations
2023-03-05
Patil Neena M
sold (taxes)
-274,566
142
-1,923
evp & chief legal officer
2023-03-05
Carr Patricia
sold
-161,594
140
-1,148
svp, chief accounting officer
2023-03-05
Iannone Robert
sold (taxes)
-324,682
142
-2,274
evp, global head of research a
2023-03-05
Swisher Daniel N JR
sold (taxes)
-774,724
142
-5,426
president and coo

1–10 of 50

Bruce C. Cozadd
3200
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.

JAZZ Income Statement

2022-12-31
CONSOLIDATED STATEMENTS OF INCOME (LOSS) - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenues:   
Total revenues$ 3,659,374$ 3,094,238$ 2,363,567
Operating expenses:   
Cost of product sales (excluding amortization of acquired developed technologies)540,517440,760148,917
Selling, general and administrative1,416,9671,451,683854,233
Research and development590,453505,748335,375
Intangible asset amortization599,169525,769259,580
Impairment charge133,6480136,139
Acquired in-process research and development444,1480251,250
Total operating expenses3,724,9022,923,9601,985,494
Income (loss) from operations(65,528)170,278378,073
Interest expense, net(288,242)(278,766)(99,707)
Foreign exchange loss(19,014)(4,350)(3,271)
Income (loss) before income tax expense (benefit) and equity in loss of investees(372,784)(112,838)275,095
Income tax expense (benefit)(158,645)216,11633,517
Equity in loss of investees9,9217142,962
Net income (loss)$ (224,060)$ (329,668)$ 238,616
Net income (loss) per ordinary share:   
Basic (in dollars per share)$ (3.58)$ (5.52)$ 4.28
Diluted (in dollars per share)$ (3.58)$ (5.52)$ 4.22
Weighted-average ordinary shares used in per share calculations - basic (in shares)62,53959,69455,712
Weighted-average ordinary shares used in per share calculations - diluted (in shares)62,53959,69456,517
Product sales, net   
Revenues:   
Total revenues$ 3,641,429$ 3,079,001$ 2,346,660
Royalties and contract revenues   
Revenues:   
Total revenues$ 17,945$ 15,237$ 16,907

JAZZ Balance Sheet

2022-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 881,482$ 591,448
Accounts receivable, net of allowances of $17,843 and $13,813 at December 31, 2022 and 2021, respectively651,493563,360
Inventories714,0611,072,721
Prepaid expenses91,912131,413
Other current assets267,192252,392
Total current assets2,606,1402,611,334
Property, plant and equipment, net228,050256,837
Operating lease assets73,32686,586
Intangible assets, net5,794,4377,152,328
Goodwill1,692,6621,827,609
Deferred tax assets, net376,247311,103
Deferred financing costs9,25412,029
Other non-current assets55,13940,813
Total assets10,835,25512,298,639
Current liabilities:  
Accounts payable90,758100,298
Accrued liabilities803,255666,304
Current portion of long-term debt31,00031,000
Income taxes payable7,7179,608
Deferred revenue4632,093
Total current liabilities933,193809,303
Deferred revenue, non-current0463
Long-term debt, less current portion5,693,3416,018,943
Operating lease liabilities, less current portion71,83887,200
Deferred tax liabilities, net944,3371,300,541
Other non-current liabilities106,812116,998
Commitments and contingencies (Note 14)
Shareholders’ equity:  
Ordinary shares, nominal value $0.0001 per share; 300,000 shares authorized; 63,214 and 61,633 shares issued and outstanding at December 31, 2022 and 2021, respectively66
Non-voting euro deferred shares, €0.01 par value per share; 4,000 shares authorized, issued and outstanding at both December 31, 2022 and 20215555
Capital redemption reserve472472
Additional paid-in capital3,477,1243,534,792
Accumulated other comprehensive loss(1,125,509)(400,360)
Retained earnings733,586830,226
Total shareholders’ equity3,085,7343,965,191
Total liabilities and shareholders’ equity$ 10,835,255$ 12,298,639